The molecular pathology of Barrett's esophagus.
暂无分享,去创建一个
[1] H. Nekarda,et al. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] J. V. van Lanschot,et al. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation , 1998, The Journal of pathology.
[3] D. Beer,et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. , 1997, Cancer research.
[4] J. Goldenring,et al. Increased immunoreactivity for Rab11, a small GTP-binding protein, in low-grade dysplastic Barrett's epithelia. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[5] N. Altorki,et al. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma. , 1997, The Journal of thoracic and cardiovascular surgery.
[6] D. Beer,et al. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas , 1997, Oncogene.
[7] Jan-Gowth Chang,et al. Aberrant FHIT transcripts in cancerous and corresponding non‐cancerous lesions of the digestive tract , 1997, International journal of cancer.
[8] Suna Wang,et al. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC) , 1997, Oncogene.
[9] G. Thomas,et al. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers , 1997, International journal of cancer.
[10] N. Altorki,et al. Epidemiology and molecular biology of Barrett's adenocarcinoma. , 1997, Seminars in surgical oncology.
[11] W. Hop,et al. Reduced expression of the cadherin–catenin complex in oesophageal adenocarcinoma correlates with poor prognosis , 1997, The Journal of pathology.
[12] D. Wong,et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. , 1997, Cancer research.
[13] V. Álvarez,et al. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. , 1997, Journal of clinical pathology.
[14] R. Odze,et al. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[15] W. Giaretti. Aneuploidy Mechanisms in Human Colorectal Preneoplastic Lesions and Barrett’s Esophagus. Is There a Role for K-Ras and p53 Mutations? , 1997, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[16] H. Appelman,et al. Tumors of the Esophagus and Stomach , 1996 .
[17] C. Moskaluk,et al. p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. , 1996, Human pathology.
[18] S. Kern,et al. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. , 1996, Cancer research.
[19] A. Hagemeijer,et al. Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia. , 1996, Cancer genetics and cytogenetics.
[20] Carissa A. Sanchez,et al. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. , 1996, Oncogene.
[21] L. Liotta,et al. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. , 1996, Cancer research.
[22] J. Goldenring,et al. Rab11 is an apically located small GTP-binding protein in epithelial tissues. , 1996, The American journal of physiology.
[23] C. Croce,et al. The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.
[24] J. Roth,et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. , 1996, The Journal of thoracic and cardiovascular surgery.
[25] Scott E. Kern,et al. DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.
[26] J. Sloan,et al. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. , 1995, Cancer research.
[27] J. Bartek,et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.
[28] J. Field,et al. Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. , 1995, British Journal of Cancer.
[29] S. Nagata,et al. The Fas death factor , 1995, Science.
[30] F. Bosman,et al. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus , 1995, The Journal of pathology.
[31] S. Steinberg,et al. Expansion of the Ki‐67 proliferative compartment correlates with degree of Dysplasia in Barrett's esophagus , 1995, Cancer.
[32] G. Thomas,et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.
[33] V. Rusch,et al. The management of high grade dysplasia and early cancer in Barrett's esophagus , 1994, Cancer.
[34] H. Höfler,et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. , 1994, Cancer research.
[35] J. Behrens. Cadherins as determinants of tissue morphology and suppressors of invasion. , 1994, Acta anatomica.
[36] Carissa A. Sanchez,et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. , 1994, Gastroenterology.
[37] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[38] A. Mercurio,et al. Poorly differentiated colon carcinoma cell lines deficient in alpha-catenin expression express high levels of surface E-cadherin but lack Ca(2+)-dependent cell-cell adhesion. , 1993, Cell adhesion and communication.
[39] Patricia L. Blount,et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.
[40] D. Beer,et al. Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas , 1993, International journal of cancer.
[41] Patricia L. Blount,et al. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[42] Leland Hartwell,et al. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.
[43] P. Pairolero,et al. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? , 1992, The Annals of thoracic surgery.
[44] K. Lewin,et al. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. , 1992, Human pathology.
[45] G. Sutherland. Chromosomal fragile sites. , 1991, Genetic analysis, techniques and applications.
[46] J. Fraumeni,et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.
[47] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[48] H. Barr,et al. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. , 1998, The American journal of pathology.
[49] T. Demeester,et al. Barrett's esophagus. The significance of p53 in clinical practice. , 1997, Annals of surgery.
[50] J. Crawford. Membrane trafficking and the pathologist: esophageal dysplasia. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[51] C. Férec,et al. Molecular analysis of the TP53 gene in Barrett's adenocarcinoma , 1996, Human mutation.
[52] J. Roth,et al. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. , 1994, American journal of surgery.
[53] S. Spechler,et al. Barrett's esophagus. , 1994, Seminars in oncology.
[54] D. Notterman,et al. The p53 tumor suppressor gene. , 1994, The Journal of laboratory and clinical medicine.
[55] P. Blount,et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.
[56] B. Reid,et al. Progression to cancer in Barrett's esophagus is associated with genomic instability. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[57] S. Ming. Tumors of the esophagus and stomach , 1973 .